Quellen
- 01
Heres S .
et al .
Attitudes of psychiatrists toward antipsychotic depot medication.
J Clin Psychiatry.
2006;
67 (12)
1948-53
- 02
Parellada E .
et al .
Patients in the early phases of schizophrenia and schizoaffective disorders effectively
treated with risperidone long-acting injectable.
J Psychopharmacol.
2005;
19
5-14
- 03
Pajonk FG .
et al .
Psychopharmacological treatment of schizophrenia - How is medication favoured by the
patient? First result of the FAME I-Study.
Pharmacopsychiatry.
2005;
38 (5)
268
- 04
Schmitz FS .
et al .
Psychopharmacological treatment of schizophrenia - how is medication favoured by the
patients?.
Schiz Res.
2006;
81 (Suppl)
596
- 05 Herres S . et al . Data on file.
- 06
Lieberman JA .
et al .
Factors influencing treatment response and outcome of first-episode schizophrenia:
implications for understanding the pathophysiology of schizophrenia.
J Clin Psychiatry.
1996;
57(Suppl 9)
5-9
- 07 Berufsverband Deutscher Psychologinnen und Psychologen: http://www.bdp-verband.org/psychologie/glossar/suizid.shtml
.
- 08 Möller HJ et al. Duale Reihe: Psychiatrie und Psychotherapie. Stuttgart: Thieme
2001.
- 09 American Psychiatric Association. Practice Guideline for the Treatment of Patients
With Schizophrenia, Beilage zu Am J Psychiatry, 1997; 154: 4.
- 10
Thomopson PM .
et al .
Mapping adolescent brain change reveals dynamic wave of accelerated gray matter loss
in very early-onset schizophrenia.
PNAS.
2001;
98
11650-5
- 11
Robinson DG .
et al .
Predictors of relapse following response from a first episode of schizophrenia or
schizoaffective disorder.
Arch Gen Psychiatry.
1999;
56
241-7
- 12 Byerly MJ . et al . A Comparison on Clinician Versus Electronic Monitoring of Antipsychotic
Adherence Poster # 176, presented at the 156th APA Meeting; 2003.
- 13
Mannaert E .
et al .
Plasma concentration profile of long-acting injectable risperidone after multiple
doses, compared with oral formulation.
Int J Neuropsychopharmacol.
2004;
7(Suppl 2)
S39
- 14
Fleischhacker WW .
et al .
Treatment of Schizophrenia With Long-Acting Injectable Risperidone: A 12-Month Open-Label
Trial of the First Long-Acting Second-Generation Antipsychotic.
J Clin Psychiatry.
2003;
64
1250-7
- 15
Möller HJ .
et al .
.
Efficacy and safety of direct transition to risperidone long-acting injectable in
patients treated with various antipsychotic therapies.
Int Clin Psychopharmacol.
2005;
20
121-30
01 Favoured Medication-Studie
02 Medical Event Monitoring System
03 Switch to Risperidone Microspheres
04 Extrapyramidal Symptom Rating Scale
